Agilon Health (NYSE:AGL) Shares Gap Up After Better-Than-Expected Earnings

Agilon Health, Inc. (NYSE:AGL)’s share price gapped up prior to trading on Thursday following a better than expected earnings announcement. The stock had previously closed at $27.85, but opened at $43.59. Agilon Health shares last traded at $53.5980, with a volume of 816,939 shares traded.

The company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.04 by $0.76. The firm had revenue of $1.42 billion during the quarter, compared to analyst estimates of $1.38 billion. Agilon Health had a negative return on equity of 120.82% and a negative net margin of 6.60%.

Key Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon reported stronger‑than‑expected Q1 results — EPS $1.80 vs. consensus ~$1.04 and revenue $1.42B vs. ~$1.38B, highlighting better operating performance this quarter. BusinessWire Q1 Results
• Positive Sentiment: Management raised full‑year 2026 guidance for total revenues, medical margin and Adjusted EBITDA and issued Q2 revenue guidance of roughly $1.4B–$1.5B, signaling confidence in the outlook. Guidance/Press Release
• Positive Sentiment: Market reacted strongly to the results and guidance — reports show the stock jumped sharply after the print, reflecting investor enthusiasm. Yahoo Finance: Stock Jumps
• Positive Sentiment: Robert W. Baird raised its price target from $20 to $35 (maintaining a neutral rating), providing additional analyst support for upside potential. Benzinga: Baird PT Raise
• Neutral Sentiment: Detail and color from the Q&A are available in call transcripts for investors who want operational and margin detail. InsiderMonkey Transcript Seeking Alpha Transcript
• Neutral Sentiment: Analyst writeups (e.g., Zacks) emphasize the EPS and revenue beat versus consensus and provide metric‑level context for investors assessing sustainability. Zacks Note
• Negative Sentiment: J.P. Morgan issued a downgrade (coverage action reported), a sign that some institutional analysts remain cautious despite the beat and guidance raises. MSN: JP Morgan Downgrade

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Benchmark boosted their target price on shares of Agilon Health to $13.00 and gave the stock a “buy” rating in a research report on Thursday, April 2nd. Barclays reduced their target price on Agilon Health from $25.00 to $12.50 and set an “underweight” rating on the stock in a report on Friday, February 27th. Robert W. Baird lifted their price objective on shares of Agilon Health from $20.00 to $35.00 and gave the stock a “neutral” rating in a report on Thursday. Citigroup dropped their price objective on shares of Agilon Health from $21.25 to $18.75 and set a “neutral” rating on the stock in a report on Tuesday, March 3rd. Finally, JPMorgan Chase & Co. cut shares of Agilon Health from a “neutral” rating to an “underweight” rating and set a $21.00 price objective on the stock. in a report on Monday. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Agilon Health currently has a consensus rating of “Hold” and an average price target of $42.70.

Hedge Funds Weigh In On Agilon Health

Several institutional investors have recently added to or reduced their stakes in AGL. CenterBook Partners LP increased its position in Agilon Health by 492.4% in the 3rd quarter. CenterBook Partners LP now owns 11,428,027 shares of the company’s stock valued at $11,771,000 after acquiring an additional 9,499,012 shares in the last quarter. Pallas Capital Advisors LLC acquired a new position in Agilon Health during the 4th quarter worth $59,000. JPMorgan Chase & Co. raised its position in shares of Agilon Health by 209.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,105,297 shares of the company’s stock valued at $2,168,000 after acquiring an additional 1,425,052 shares during the last quarter. Symphony Financial Services Inc. increased its holdings in Agilon Health by 51.6% in the third quarter. Symphony Financial Services Inc. now owns 47,000 shares of the company’s stock valued at $48,000 after purchasing an additional 16,000 shares during the last quarter. Finally, Quantbot Technologies LP bought a new stake in Agilon Health in the third quarter valued at about $381,000.

Agilon Health Stock Up 95.0%

The business has a fifty day moving average of $17.82 and a 200 day moving average of $18.00. The firm has a market cap of $904.82 million, a P/E ratio of -2.29 and a beta of 2.29. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12.

About Agilon Health

Agilon Health (NYSE: AGL) is a healthcare company that partners with independent primary care physicians to deliver value-based care for Medicare beneficiaries. Through risk-sharing arrangements, Agilon assumes financial responsibility for patient populations, enabling physicians to focus on preventive and proactive health management. The company provides the administrative, clinical and operational infrastructure needed to support comprehensive care delivery.

Agilon’s platform encompasses data analytics, care management, patient engagement tools and population health programs.